RxDoctor Payments Data

Jorge Melendez Hernandez, MD

Gastroenterology · Vega Baja, PRNPI 1841491321

Payments from drug & device makers

$2,399in general payments, 2019–2025

Across 61 payments — averaging $39.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • E.r. Squibb & Sons, L.L.C.$604
  • Madrigal Pharmaceuticals$169
  • Takeda Pharmaceuticals U.S.A., Inc.$106
  • Boston Scientific$99
  • Sanofi$22
  • plus $53 from 3 others

What the payments were for

  • Food & beverage$2,399100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,399 in reported general payments places this provider in the 55th percentile of 198 gastroenterology providers in Puerto Rico.

See all gastroenterology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$5,879
Medicare patients
16
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide139$100,435
SuprepSodium, Potassium,mag Sulfates236$27,915
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates242$19,809
Mesalamine36$16,137
Sucralfate53$5,456
Mesalamine DrMesalamine12$5,024
CholestyramineCholestyramine (With Sugar)16$3,304
Dicyclomine Hcl146$3,192
Omeprazole443$2,920
Ursodiol19$2,675
SutabSod Sulf/Pot Chloride/Mag Sulf15$2,515
Lubiprostone15$1,529
Azathioprine26$1,323
Famotidine161$1,195
Clarithromycin30$1,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,346$100,435139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 198 gastroenterology providers in Puerto Rico.

Other gastroenterology in Vega Baja

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →